Abstract
Aim:
To investigate the thrombolytic efficacy, ideal dosage and administration of native recombinant staphylokinase (r-SAK).
Methods:
Forty New Zealand rabbits were randomly assigned into the control, r-SAK low-dose, medial-dose, high-dose, single bolus, allied therapy, recombinant streptokinase (r-SK) and urokinase (UK) groups. The right femoral artery thrombosis models were made by balloon injury, and 120 min after the injury, the thrombolytic agents were infused through the rabbits' parallel-ear vein.
Results:
(1) 2 h after balloon injury, the pulse pressures of the right femoral arteries reduced to 0 or less than 10% of that of left femoral arteries in all groups; (2) after thrombolytic therapy, the pulse pressures in some of the femoral arteries markedly enhanced to more than 50% of that of left femoral arteries; (3) the reopening rates in the r-SAK medial and high-dose groups were significantly higher than that of the control. The reopening rate of the same dose native r-SAK was significant higher than that of UK and r-SK; (4) the patency score of the right femoral arteries tended to be better in the r-SAK medial and high-dose groups than that of the low-dose group, and the time to reopening in the allied therapy group tended to be shorter.
Conclusion:
(1) r-SAK has a definite thrombolytic effect on the femoral artery thrombus of rabbits; (2) single bolus is an effective manner of r-SAK therapy, and r-SAK allied therapy with heparin may shorten the time to recanalization; (3) the efficacy of the same dose native r-SAK was superior to that of r-SK and UK.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Toombs CF . New directions in thrombolytic therapy. Curr Opin Pharmacol 2001; 1: 164–8.
Szemraj J, Walkowiak B, Kawecka I, Janiszewska G, Buczko W, Bartkowiak J, et al. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity-a staphylokinase variant. I. In vitro study. J Thromb Haemost 2005; 3: 2156–65.
Li CJ, Huang J, Yang GP, Xu YN, Lu L, Feng ZQ . An animal model of the femoral artery thrombosis in rabbit by balloon injury. Acta Univ Med Nanjing 2001; 21: 277–80.
Rebello SS, Driscoll EM, Lucchesi BR . TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog. Stroke 1997; 28: 1789–96.
Collen D, Cock FD, Stassen FM . Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation 1993; 87: 996–1006.
Vanderschueren S, Barrios L, Kerdsinchai P, De Man F, Muyldermans L, Collen D, et al. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group. Circulation 1995; 92: 2044–9.
Vanderschueren S, Dens J, Kerdsinchai P, Desmet W, Vrolix M, De Man F, et al. Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am Heart J 1997; 134: 213–9.
Tang QQ, Zhang XX, Yu M, Song HY . Isolation, purification and crystallization of recombinant staphylokinase (r-Sak). Pharm Biotech 1997; 4: 1–4.
Merhi Y, Guidoin R, Provost P, Leung TK, Lam JY . Increase of neutrophil adhesion and vasoconstriction with platelet deposition after deep arterial injury by angioplasty. Am Heart J 1995; 129: 445–51.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, Cj., Huang, J., Yang, Zj. et al. Thrombolytic efficacy of native recombinant staphylokinase on femoral artery thrombus of rabbits. Acta Pharmacol Sin 28, 58–65 (2007). https://doi.org/10.1111/j.1745-7254.2007.00455.x
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00455.x
